The latest report by IMARC Group, titled “Anti-Rheumatics Market Report by Type (Prescription-based Drugs, Over-the-Counter Drugs), Drug Class (Disease Modifying Anti-Rheumatics Drugs (DMARD's), Nonsteroidal Anti-Inflammatory Drugs (NSAID's), Corticosteroids, Uric Acid Drugs, and Others), Route of Drug Administration (Oral, Parenteral, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce), and Region 2024-2032“, The global anti-rheumatics market size reached US$ 64.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 80.4 Billion by 2032, exhibiting a growth rate (CAGR) of 2.4% during 2024-2032.

Autoimmune and inflammatory rheumatic disorders impact the joints, tendons, ligaments, bones, and muscles, causing symptoms such as joint pain, stiffness, sensitivity, and swelling. Additional manifestations may include weight loss, fever, fatigue, and weakness. Treatment usually involves a variety of medications like anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), and medications for controlling uric acid levels. The primary goal of these medications is to prevent joint damage, reduce inflammation, and halt the advancement of the disease process.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/anti-rheumatics-market/requestsample

Anti-Rheumatics Market Trends and Drivers:

The global market is currently on an upward trajectory, fueled by a growing elderly population and a rise in rheumatoid arthritis cases. Unhealthy eating habits, lack of physical activity, and the increasing rates of obesity are exacerbating the symptoms of rheumatoid arthritis. Additionally, the uptick in diabetes diagnoses is playing a role in expanding the market. There is a rising awareness about various anti-rheumatic treatments, driving market growth. Moreover, increased investments in research and development are leading to the introduction of new medications and cost-saving initiatives. Factors like higher disposable incomes, improved affordability of treatments for rheumatoid arthritis, and easy access to both prescription and over-the-counter drugs are also contributing positively to market growth.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Type:

  • Prescription-based Drugs
  • Over-the-Counter Drugs

Breakup by Drug Class:

  • Disease Modifying Anti-Rheumatics Drugs (DMARD's)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

Breakup by Route of Drug Administration:

  • Oral
  • Parenteral
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Competitive Landscape with Key Player:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celltrion Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnsons
  • Pfizer Inc.
  • Sanofi SA

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145